GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Treatment of primary neonatal mouse cardiomyocytes with liraglutide increases cAMP formation and reduces apoptosis, as indicated by inhibition of TNFa induction of caspase 3 activity [614].”
BackgroundInfluentialSelf-citationPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Liraglutide (10–100 nM) also reduced TNF-a (100 ng/ml, 24 hr)-induced caspase-3 activation in murine cardiomyocytes, actions abolished by Ex-9 (10 mM) (Noyan-Ashraf et al., 2009).”
BackgroundSelf-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“443 These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid pro fi les, 444 preserving endothelial integrity and regulating endothelial function, 445 as well as modulating in fl ammatory processes.”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-Renewing Resident Cardiac Macrophages Limit Adverse Remodeling Following Myocardial Infarction
Dick, S. A., Macklin, J. A., Nejat, S., Momen, A., Clemente-Casares, X., Althagafi, M. G., Chen, J., Kantores, C., Hosseinzadeh, S., Aronoff, L., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0272-2 · Cited by 883
“All left anterior descending (LAD) artery ligations were performed as previously described 44 .”
Self-citationGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationZangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationFerdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008300 · Cited by 562
“, 2008; 2010a); 2) GLP-1 analogs, such as liraglutide (Noyan-Ashraf et al., 2009) and exenatide (Timmers et al.”
BackgroundHuynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
“Stromal cell-derived factor-1 (SDF-1 ) SDF-1 is a 7.97-kDa chemokine secreted from multiple cell types that promotes homing of endothelial pro- Figure 5. genitor cells to sites of cellular injury.”
BackgroundMethodInfluentialSelf-citationKim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Self-citationRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“Furthermore in a model of myocardial infarction, liraglutide reduced infarction size (18) associated with reduced TNF-a in cardiac tissue (19).”
BackgroundDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Self-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Experiments in rodents showed that GLP-1R agonists can reduce myocardial infarct size and improve left ventricular function, including better wall motility and ejection fractions (Nikolaidis et al., 2004b; Noyan-Ashraf et al., 2009).”
BackgroundCardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Self-citationPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
“ocytes and exert direct effects in the cardiovascular system (3).”
Self-citationIncretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
“The GLP-1R is expressed in cardiomyocytes and endothel ial cel ls , and preclinical studies demonstrate that GLP-1R activation is associated with substantial cardioprotect ion and reduced infarct s ize in experimental models of coronary artery ischemia (9,10).”
BackgroundSelf-citationGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
“Activation of GLP-1R signaling rapidly improves ventricular function in the context of transient ischemia in preclinical and clinical studies (14) and reduces infarct size in experimentalmodels of ischemia secondary to coronary artery ligation (15, 16).”
BackgroundSelf-citationPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“restoration of signaling pathways disrupted by diverse stress stimuli (139, 191, 192, 195).”
BackgroundRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“36) were abolished by pre-treatment with a DPP-4 inhibitor, suggesting that GLP-1(7-36) is pro-peptide for GLP-1(9-36) in this setting (67).”
BackgroundMethodInfluentialSelf-citationExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
“Similar cardioprotective effects of native GLP-1(227) and liraglutide have been observed in a murine model of ischaemia following coronary artery occlusion.(228) Several small studies have evaluated the effect of GLP-1 in both diabetic and non-diabetic humans with CHF.”
BackgroundSauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
“More recently, GLP-1 (9-36), a peptide metabolite derived from native GLP-1 (7From the (1)Samuel Lunenfeld Research Institute, Mt.”
BackgroundMethodInfluentialSelf-citationShiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
“22 However, liraglutide effectively normalized or increased phosphorylation of other important signaling molecules such as GSK-3 β and ERK1/2 in the hearts of obese mice at this later stage (Figure 4C and D).”
BackgroundInfluentialSelf-citationSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Preclinical studies demonstrate that administration of GLP1RAs reduces infarct size, while improving ventricular function and survival in mice with experimental myocardial infarction 124 .”
Self-citationThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationHendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
“[17] Noyan-Ashraf MH, Momen MA, Ban K, et al.”
BackgroundBan, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., & Husain, M. (2010) · Endocrinology · doi:10.1210/en.2009-1197 · Cited by 224
Self-citationWang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
“that incretin-based therapies have brought many benefits for diabetic patients, such as protection against ischaemia and reperfusion [53,54], improvement of cardiac function [55–58], lipid profile improvement [30,59,60] and improved endothelial function [61–63].”
BackgroundMells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
“The same group also reported that a GLP-1 receptor agonist called liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice [4].”
RetractedHydrolyzed Infant Formula and Early β-Cell Autoimmunity: A Randomized Clinical Trial
Knip, M., Åkerblom, H. K., Becker, D., Dosch, H.-M., Dupre, J., Fraser, W., Howard, N., Ilonen, J., Krischer, J. P., Kordonouri, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.5610 · Cited by 167
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“In contrast, GLP1R activation inhibits apoptosis in other cell types including islet beta cells, cardiomyocytes and neurons [46–48].”
BackgroundSelf-citationTaking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
Bayeva, M., Sawicki, K. T., & Ardehali, H. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000433 · Cited by 170
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
“Liraglutide reduced infarct size and increased survival after myocardial infarction (MI) in mice and reduced mortality from cardiac rupture and improved cardiac output in a mouse model of MI [22,23].”
BackgroundNeuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 159
Ye, Y., Keyes, K. T., Zhang, C., Perez-Polo, J. R., Lin, Y., & Birnbaum, Y. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00867.2009 · Cited by 157
Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149
“Interestingly, we observed a stimulation of in vivo adipogenesis, albeit reduced glucose level and reduced weight gain as reported, previously (36).”
BackgroundResultTashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147
“However, in a similar mouse model, perioperative mortality was reduced, infarction size was decreased (by 27% on day 28 postinfarction), cardiac hypertrophy was reduced, cardiac performance was improved, and the risk of cardiac rupture was decreased after pretreatment with liraglutide for 7 days before MI”
BackgroundUssher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 147
“Fifth, although the cardioprotective actions of liraglutide in mice require the GLP-1R [10,14], cardioprotection with liraglutide in mice with experimental MI is independent of the cardiomyocyte GLP-1R.”
BackgroundMethodInfluentialSelf-citationGlucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 149
“Furthermore, intraperitoneal administration of liraglutide in mice before coronary artery occlusion reduced infarct size and cardiac rupture and improved cardiac output [48].”
BackgroundIncretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
“Albiglutide (formerly known as albugon) is a long-acting GLP-1R agonist, developed by GlaxoSmithKline through the genetic fusion of two repeats of human GLP-1(7-36) molecules to recombinant human albumin.”
BackgroundInfluentialThe Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 144
“The most striking results were observed in in vivo studies with longer follow-up times, particularly the Timmers study in pigs (3 days) [40] and the Noyan–Ashraf study in mice (28 days) [41].”
ResultVinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136
Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 141
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
“Evidence from pre-clinical studies suggests that liraglutide may have beneficial effects on atherosclerotic plaque formation, progression and its stability [25], in addition to cardioprotective effects leading to improved outcomes and enhanced survival after acute myocardial infarction [26].”
BackgroundKoehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 136
“Surprisingly, unlike findings observed in -cells, cardiomyocytes, and neurons (26, 36, 37), where GLP-1, acting through cAMP, enhances cell proliferation and/or survival, Ex-4 or Fsk induced apoptosis under serum-free conditions in CT26 cells and inhibited cell proliferation in the presence of serum.”
ResultSelf-citationYounce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
dos SANTOS, L., Salles, T. A., Arruda-Junior, D. F., Campos, L. C. G., Pereira, A. C., Barreto, A. L. T., Antônio, E. L., Mansur, A. J., Tucci, P. J. F., Krieger, J. E., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000057 · Cited by 136
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
GLP-1 and cardioprotection: from bench to bedside
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs123 · Cited by 136
Liu, Q., Anderson, C. M., Broyde, A., Polizzi, C. J., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 127
“However, the cardioprotective effects of the GLP-1R agonist liraglutide in a mouse MI model were found to be independent of weight reduction [9].”
Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 132
“…metabolism and may involve activation of cyclic GMP/cyclic AMP-dependent pathways and pro-survival kinases such as PI3K, Akt, glycogen synthase kinase-3b, p70s6 kinase, ERK1/2 and p38 MAPK (Bose et al., 2005a; 2007; Zhao et al., 2006; Ban et al., 2008; Xie et al., 2008; Noyan-Ashraf et al., 2009).”
BackgroundChen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 123
“014 Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice.(5) Nikolaidis et al found that GLP-1 infusion improved regional and global left ventricular function in patients with AMI.”
BackgroundAMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation
Daskalopoulos, E. P., Dufeys, C., Bertrand, L., Beauloye, C., & Horman, S. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.01.001 · Cited by 126
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 130
Dai, Y., Mehta, J. L., & Chen, M. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6463-z · Cited by 117
“In the context of vascular inflammation that is commonly observed in diabetes and atherosclerosis, the effects of liraglutide on ET-1 expression and IL-6 formation in endothelial cells described in this study may relate to the potentially beneficial effects of liraglutide in clinical and experimental studies [7–9, 19].”
Therapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 123
“receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.”
BackgroundGiorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 113
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 116
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“05), compared with 7 days of treatment with saline (63).”
BackgroundRizzo, M., Chandalia, M., Patti, A. M., Bartolo, V. D., Rizvi, A. A., Montalto, G., & Abate, N. I. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 115
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma
Rothhammer-Hampl, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., & Bosserhoff, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3337-8 · Cited by 117
Monji, A., Mitsui, T., Bando, Y., Aoyama, M., Shigeta, T., & Murohara, T. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00990.2012 · Cited by 109
“GLP-1, one of the incretine hormones, has been focused not only as an alternative therapeutic 281 target for diabetes but also its pleiotropic effects on cardiovascular disease, including heart failure 282 related to pacing-induced heart failure (22), myocardial infarction (23), and obesity (24).”
BackgroundGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 110
Chen, A., Chen, Z., Xia, Y., Lu, D., Yang, X., Sun, A., Zou, Y., Qian, J., & Ge, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.142 · Cited by 108
Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Self-citationBao, W., Aravindhan, K., Alsaid, H., Chendrimada, T. P., Szapacs, M. E., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 106
“Numerous studies examining the cardioprotective benefit of GLP-1 [4–7], exentatide [7,9] and liraglutide [10] in models of I/R have been performed.”
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104
Self-citationAronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104
“The latter was primarily mediated through upregulation of pro-survival pathways (34, 35).”
BackgroundMethodInoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., & Takayanagi, R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.026 · Cited by 108
Mitchell, R. K., Mondragon, A., Chen, L., McGinty, J., French, P. M. W., Ferrer, J. P., Thorens, B., Hodson, D. J., Rutter, G. A., & Xavier, G. D. S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu553 · Cited by 103
“Responsiveness to incretin treatment was assessed by co-injection of liraglutide [200 μg/kg (66); Bachem, Bubendorf, Switzerland] with glucose during an intraperitoneal glucose tolerance test.”
MethodPicatoste, B., Ramírez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078330 · Cited by 104
“peroxisome proliferator activating receptor-δ (PPARδ) [28, 29].”
Liraglutide: the therapeutic promise from animal models
Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 102
The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
Ye, Y., Perez-Polo, J. R., Aguilar, D. A., & Birnbaum, Y. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0216-6 · Cited by 104
“In contrast, the same investigators reported that liraglutide did not increase Akt and glycogen synthase kinase-b (GSKb) phosphorylation in GLP-1R mice, as it did in wild-type mice [121].”
Mulvihill, E. E., Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W. A., Abdullah, T., Baggio, L. L., & Drucker, D. J. (2015) · Diabetes · doi:10.2337/db15-1224 · Cited by 104
“Doses of MK-0626 and liraglutide were based on pilot studies (13,15) to achieve equivalent glucose control without reduction of food intake or body weight.”
BackgroundSelf-citationTherapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 107
Chen, W. R., Chen, Y. D., Tian, F., Yang, N., Cheng, L. Q., Hu, S. Y., Wang, J., Yang, J. J., Wang, S. F., & Gu, X. F. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005146 · Cited by 103
“Liraglutide, a GLP-1 analog, was reported to reduce infarct size and improve cardiac output in normal and diabetic mice.(8) Several studies have shown that exenatide (another GLP-1 analog) protects against ischemia-reperfusion injury and reduces infarct size in patients with STEMI.”
BackgroundHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Bentley–Lewis, R., Aguilar, D. A., Riddle, M. C., Claggett, B. L., Díaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L., Lawson, F. C., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 103
Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C. O. C., Skov, L., Knop, F. K., & Vilsbøll, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12629 · Cited by 97
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 107
“Moreover, animal studies with GLP-1 agonists suggest the potential to reduce infarct size and improve survival after myocardial infarction [65-67].”
BackgroundTate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96
“Notably, exendin-4 was infused from 4 weeks, at a concentration comparable to previous experimental studies [32, 34], once elevated glucose levels had been achieved, to further reflect the likely clinical scenario.”
Hausenloy, D. J., Whittington, H. J., Wynne, A. M., Begum, S. S., Theodorou, L., Riksen, N. P., Mocanu, M. M., & Yellon, D. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-154 · Cited by 96
“An alternative strategy to DPP-4 inhibition would be to administer clinically available GLP-1 analogues such as Liraglutide [36] and Exenatide [37,38] which are resistant to DPP-4 and are also cardioprotective in animal studies.”
BackgroundAre targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 97
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
“Cardiovascular Effects Experimental evidence suggests that GLP-1 can exert cardioprotective effects through a direct activation of antiapoptotic mechanisms in cardiomyocytes [10].”
BackgroundMultifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆
Balakumar, P., & Jagadeesh, G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.07.003 · Cited by 95
Wu, L., Wang, K., Wang, W., Zheng, W., Wang, P., Liu, L., & Wang, D. W. (2018) · Aging Cell · doi:10.1111/acel.12763 · Cited by 98
“GLP-1R agonists and DPP-4 inhibitors have beneficial effects on the cardiovascular system (Ban et al., 2008; Noyan-Ashraf et al., 2009; Timmers et al., 2009).”
Background
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.